A Comprehensive Overview of the Past, Current, and Future Randomized Controlled Trials in Hepatic Encephalopathy

Background: Hepatic encephalopathy (HE) caused by cirrhosis has severe consequences on an individual’s lifespan, leading to long-term liver complications and potentially life-threatening outcomes. Despite recent interest in this condition, the effectiveness of secondary prophylaxis involving rixafimin, lactulose, or L-ornithine L-aspartate (LOLA) may be hindered by the unique microbial profiles each patient possesses. Methods: Thus, in this manuscript, we aimed to search, identify, and gather all randomized controlled trials (RCTs) published between 2000–2023 (November) in four major academic databases such as PubMed, ISI Web of Science, Scopus, and ScienceDirect by using a controlled terminology and web strings that reunite six main keywords. We complementarily retrieved data on the ongoing RCTs. Results: Regardless of the relatively high number of results displayed (n = 75), 46.66% (n = 35) were initially deemed eligible after the first evaluation phase after removing duplicates, n = 40 (53.34%). At the second assessment stage, we eliminated 11.42% (n = 4) studies, of which n = 22 finally met the eligibility criteria to be included in the main body of the manuscript. In terms of RCTs, otherwise found in distinct stages of development, n = 3 target FMT and n = 1 probiotics. Conclusions: Although we benefit from the necessary information and technology to design novel strategies for microbiota, only probiotics and synbiotics have been extensively studied in the last decade compared to FMT.

• Publication year

  2023

• Venue

  Medicina

• Publication date

  2023-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3390/medicina59122143PMID 38138246PMCID 10744451
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prevalence and Characteristics of Covert/Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis: A Systematic Review and Meta-Analysis

  2023cited by this paper
• Hepatic Encephalopathy: Diagnostic Tools and Management Strategies.

  2023cited by this paper
• Active Clinical Trials in Hepatic Encephalopathy: Something Old, Something New and Something Borrowed

  2023cited by this paper
• Update in the treatment of the complications of cirrhosis.

  2023cited by this paper
• Hepatic encephalopathy – recent advances in treatment and diagnosis

  2023cited by this paper
• Women with cirrhosis have lower self-rated health than men

  2023influential reference
• Sex differences in clinical characteristics and outcomes associated with alcoholic hepatitis

  2023cited by this paper
• Hepatic Encephalopathy: Current and Emerging Treatment Modalities.

  2022cited by this paper
• Evidence-based approach to management of hepatic encephalopathy in adults

  2022cited by this paper
• EASL Clinical Practice Guidelines on the management of hepatic encephalopathy.

  2022cited by this paper
• Hepatic encephalopathy

  2022cited by this paper
• Current approaches to hepatic encephalopathy.

  2022cited by this paper
• Effect of probiotics on hemodynamic changes and complications associated with cirrhosis: A pilot randomized controlled trial

  2022cited by this paper
• Systematic Review and Meta-Analysis on the Effects of Lactulose and Rifaximin on Patient-Reported Outcomes in Hepatic Encephalopathy

  2022cited by this paper
• The Role of Intestinal Bacteria and Gut–Brain Axis in Hepatic Encephalopathy

  2021cited by this paper
• Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy.

  2020cited by this paper
• Gender Differences Among Patients Hospitalized With Cirrhosis in the United States

  2020influential reference
• Sex disparities in waitlisting and liver transplant for acute liver failure

  2020influential reference
• A Double-Blind, Randomized Placebo-Controlled Trial of Probiotic Lactobacillus casei Shirota in Stable Cirrhotic Patients

  2020cited by this paper
• Epidemiology of Hepatic Encephalopathy.

  2020cited by this paper
• Pathophysiology of Hepatic Encephalopathy.

  2020cited by this paper
• Neuroinflammation in Murine Cirrhosis Is Dependent on the Gut Microbiome and Is Attenuated by Fecal Transplant

  2020cited by this paper
• Donor Screening for Fecal Microbiota Transplantation.

  2019cited by this paper
• Long-term Outcomes of Fecal Microbiota Transplantation in Patients With Cirrhosis.

  2019cited by this paper
• Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant.

  2019cited by this paper
• Supplementation with Synbiotics and/or Branched Chain Amino Acids in Hepatic Encephalopathy: A Pilot Randomised Placebo-Controlled Clinical Study

  2019cited by this paper
• Effect of a Multistrain Probiotic on Cognitive Function and Risk of Falls in Patients With Cirrhosis: A Randomized Trial

  2019cited by this paper
• Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo‐Controlled Trial

  2019cited by this paper
• Microbial Functional Change is Linked with Clinical Outcomes after Capsular Fecal Transplant in Cirrhosis.

  2019cited by this paper
• Hepatic Encephalopathy: Definition, Clinical Grading and Diagnostic Principles

  2019cited by this paper
• Role of probiotics in the treatment of minimal hepatic encephalopathy in patients with HBV-induced liver cirrhosis

  2018cited by this paper
• Is treating the gut microbiome the key to achieving better outcomes in cirrhosis?

  2018cited by this paper
• Considerations for the cost-effective management of hepatic encephalopathy.

  2018cited by this paper
• Hepatic encephalopathy: Diagnosis and management

  2018cited by this paper
• Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo

  2018cited by this paper
• Current Management of Hepatic Encephalopathy

  2018cited by this paper
• Hepatic encephalopathy: classification and treatment.

  2018cited by this paper
• Proton Pump Inhibitor Initiation and Withdrawal affects Gut Microbiota and Readmission Risk in Cirrhosis

  2018cited by this paper
• Protective Effect of Akkermansia muciniphila against Immune-Mediated Liver Injury in a Mouse Model

  2017cited by this paper
• Effects of continuous use of probiotics before liver transplantation: A randomized, double-blind, placebo-controlled trial.

  2017cited by this paper
• Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial

  2017cited by this paper
• Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease

  2017cited by this paper
• Hepatic Encephalopathy Is Associated with Persistent Learning Impairments Despite Adequate Medical Treatment: A Multicenter, International Study

  2017cited by this paper
• Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity

  2017cited by this paper
• Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology

  2016cited by this paper
• Consequences of bile salt biotransformations by intestinal bacteria

  2016cited by this paper
• Bifidobacteria and Butyrate-Producing Colon Bacteria: Importance and Strategies for Their Stimulation in the Human Gut

  2016cited by this paper
• Efficacy of Nutritional Therapy for Patients With Cirrhosis and Minimal Hepatic Encephalopathy in a Randomized Trial.

  2016cited by this paper
• The 3‐month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis

  2016cited by this paper
• The effect of Saccharomyces boulardii in patients eligible for liver transplantation.

  2015cited by this paper
• The Effect of Lactobacillus plantarum 299v on the Incidence of Clostridium difficile Infection in High Risk Patients Treated with Antibiotics

  2015cited by this paper
• Is it time to target gut dysbiosis and immune dysfunction in the therapy of hepatic encephalopathy?

  2015cited by this paper
• Covert and Overt Hepatic Encephalopathy: Diagnosis and Management.

  2015cited by this paper
• Effect of probiotic VSL#3 in the treatment of minimal hepatic encephalopathy: A non‐inferiority randomized controlled trial

  2015cited by this paper
• Effect of Rifaximin, Probiotics, and l-Ornithine l-Aspartate on Minimal Hepatic Encephalopathy: A Randomized Controlled Trial

  2014cited by this paper
• Innovative and Emerging Technologies in GI Physiology and Disease Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function

  2014cited by this paper
• Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver

  2014influential reference
• Effect of Intestinal Microbiota Alteration on Hepatic Damage in Rats with Acute Rejection After Liver Transplantation

  2014cited by this paper
• The evidence for the use of nutritional support in liver disease

  2014cited by this paper
• Contribution of Veillonella parvula to Pseudomonas aeruginosa-Mediated Pathogenicity in a Murine Tumor Model System

  2014cited by this paper
• Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial.

  2014cited by this paper
• Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis

  2014cited by this paper
• Alterations of the human gut microbiome in liver cirrhosis

  2014cited by this paper
• Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites

  2014cited by this paper
• The role of microbiota in hepatic encephalopathy

  2014cited by this paper
• Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial.

  2014cited by this paper
• Nutritional management contributes to improvement in minimal hepatic encephalopathy and quality of life in patients with liver cirrhosis: A preliminary, prospective, open‐label study

  2013cited by this paper
• Effect of a Probiotic and Metformin on Liver Aminotransferases in Non-alcoholic Steatohepatitis: A Double Blind Randomized Clinical Trial

  2013cited by this paper
• Cirrhosis, bile acids and gut microbiota

  2013cited by this paper
• Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy

  2013cited by this paper
• Probiotic use in preventing postoperative infection in liver transplant patients.

  2013cited by this paper
• Large-Scale Survey of Gut Microbiota Associated With MHE Via 16S rRNA-Based Pyrosequencing

  2013cited by this paper
• Modulation of the fecal bile acid profile by gut microbiota in cirrhosis.

  2013cited by this paper
• Meta‐analysis: oral or enteral nutritional supplementation in cirrhosis

  2013cited by this paper
• The nutritional management of hepatic encephalopathy in patients with cirrhosis: International society for hepatic encephalopathy and nitrogen metabolism consensus

  2013cited by this paper
• Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial

  2013cited by this paper
• Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: An open labeled randomized controlled trial of lactulose versus no lactulose

  2012cited by this paper
• Hospital Readmissions Among Patients With Decompensated Cirrhosis

  2012cited by this paper
• Microbes inside—from diversity to function: the case of Akkermansia

  2012cited by this paper
• Bifidobacterium longum with Fructo-Oligosaccharides in Patients with Non Alcoholic Steatohepatitis

  2012cited by this paper
• Effect of pre- and probiotics on liver regeneration after resection: a randomised, double-blind pilot study.

  2012cited by this paper
• Perioperative synbiotic treatment to prevent infectious complications in patients after elective living donor liver transplantation: a prospective randomized study.

  2011cited by this paper
• A randomized double blind placebo controlled trial of probiotics in minimal hepatic encephalopathy.

  2011cited by this paper
• Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial.

  2011cited by this paper
• Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study.

  2011cited by this paper
• A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy

  2011cited by this paper
• Rifaximin treatment in hepatic encephalopathy.

  2010cited by this paper
• Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy

  2010cited by this paper
• Factors Affecting Compliance and Persistence with Treatment for Hepatic Encephalopathy

  2010cited by this paper
• Effect of probiotics on liver function after surgery resection for malignancy in the liver cirrhotic.

  2010cited by this paper
• Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open-Label, Randomized Controlled Trial of Lactulose, Probiotics, and No Therapy

  2010cited by this paper
• Breakfast improves cognitive function in cirrhotic patients with cognitive impairment.

  2010cited by this paper
• Effect of long‐term late‐evening snack on health‐related quality of life in cirrhotic patients

  2010cited by this paper
• Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo.

  2009cited by this paper
• Characterization of Inflammatory Bowel Disease With Urinary Metabolic Profiling

  2009cited by this paper
• Hepatic encephalopathy.

  2009cited by this paper
• Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study.

  2008cited by this paper
• An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy

  2008cited by this paper
• Probiotic Yogurt for the Treatment of Minimal Hepatic Encephalopathy

  2008cited by this paper
• Lactulose improves cognitive functions and health‐related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy

  2007cited by this paper

• A Review of Recent Advances in Fecal Microbiota Transplantation for the Treatment of Hepatic Encephalopathy

  2025cites this paper